Management

Management:

Leonard R. Borrmann, Pharm.D. is President and Chief Executive Officer. Before his appointment to Maret, Dr. Borrmann served as Chief Executive Officer of Acadia Pharmaceuticals, Inc., a privately held drug discovery company. Prior to Acadia Pharmaceuticals, Dr. Borrmann served as Vice President, Business Development of Allergan, Inc. In addition to worldwide business development, his 14-year career at Allergan included positions in clinical research and marketing. He received a Doctor of Pharmacy degree and Bachelor of Science degree in Psychobiology from the University of Southern California.

Gere S. diZerega, M.D., Maret’s Scientific Founder, is a professor and surgeon at the University of Southern California (USC). He has been a director of the Company since its inception in 1994, and continues to lead Maret’s research efforts. Dr. diZerega has many years of experience in developing medical products and consulting with major healthcare companies. He has authored five medical books, over 200 peer reviewed scientific publications and is the recipient of many national and international awards for his contributions to medical science.

Jamie Oliver, Pharm. D., is Vice President of Clinical Development. Dr. Oliver has over 17 years experience as a principal investigator in both pre-clinical and clinical experimentation in academia and the pharmaceutical industry. He joined Maret from Techniclone Corporation where he served as Vice President of Clinical and Regulatory Affairs. His experience includes IND submissions, ISS and ISE compilations, and FDA submissions (PLAs and NDAs). He had direct supervisory experience of Pharmacovigilence operations as well as primary medical support for over 30 Phase I-IV protocols.

Catherine Oyler, MBA is Director of Finance and Operations. She holds a B.S. in Biology with a minor in Neuroscience from Williams College and an MBA from The Anderson School of Management at UCLA. Her experience includes technical, marketing, and product development positions with Alkermes, Alza, and Amgen.

Spencer Johnson, is Director of Marketing. He was formerly Chief Operating Officer of Speywood Pharmaceuticals, Inc. (formerly Porton International) responsible for the commercial operations in North America. Prior to that, he was Director, Worldwide Marketing for Armour Pharmaceutical Company (Division of Rhone-Poulenc Rorer) where he held various positions in sales and marketing. He holds a B.A. from St. Joseph’s College.

Kathy Rodgers, Ph.D., is a founder of Maret and is Director of Discovery Research. She is an associate professor in the School of Medicine at the University of Southern California (USC). Dr. Rodgers has over 70 peer reviewed papers, and has served on invited committees for the World Health Organization, National Academy of Sciences, National Research Council, and National Academy of Sciences Institute of Medicine. She recently served as President of the Immunotoxicology Specialty Section of the National Society of Toxicology.

Board of Directors:

Terry E. Winters, Ph.D. is Chairman of the Board and has been a Director of the Company since 1994. He is a General Partner with the Columbine Venture Funds where he was a founder in 1983. He holds B.S. and Ph.D. degrees in Chemistry from the University of Wales. Dr. Winters also serves as a director for CollaGenex Pharmaceuticals, Afferon Corporation, Alliance Medical and iPhysician Net.

Helmer (Hank) P.K. Agersborg, Ph.D. is Vice Chairman of the Board. Dr. Agersborg was formerly President of Wyeth Ayerst’s Research (Division of American Home Products) and has extensive experience in drug development and involvement in 54 drug NDA’s and ANDA’s. Dr. Agersborg is Chairman of the Board of CollaGenex, Inc. and Chairman of the Board and President of Afferon Corporation.

Leonard R. Borrmann, Pharm.D. is President and Chief Executive Officer. Before his appointment to Maret, Dr. Borrmann served as Chief Executive Officer of Acadia Pharmaceuticals, Inc., a privately held drug discovery company. Prior to Acadia Pharmaceuticals, Dr. Borrmann served as Vice President, Business Development of Allergan, Inc. In addition to worldwide business development, his 14-year career at Allergan included positions in clinical research and marketing. He received a Doctor of Pharmacy degree and Bachelor of Science degree in Psychobiology from the University of Southern California.

Michael Collins, M.D. is a General Partner at Valley Ventures II, L.P., a Scottsdale, Arizona venture capital firm. He earned a MD degree from Baylor College of Medicine in Houston in 1984. Dr. Collins then joined a 35 physician’s multi-specialty clinic in Boulder, CO, where he successfully built a private pediatric practice. After earning an MBA from the University of Colorado, he joined Columbine Venture Funds 1992 in Denver as an associate. In 1997, he relocated to Scottsdale Arizona to help found Valley Ventures II. Dr. Collins specializes in medically related investments.

Gere S. diZerega, M.D., Maret’s Scientific Founder, is a professor and surgeon at the University of Southern California (USC). He has been a director of the Company since its inception in 1994. Dr. diZerega has many years of experience in developing medical products and consulting with major healthcare companies. He has authored five medical books, over 200 peer reviewed scientific publications and is the recipient of many national and international awards for his contributions to medical science.

James E. (Jay) Houlihan III, has been a director of Maret Corporation since 1995. He has been a General Partner with InnoCal, an investor in Maret, since 1994. He has served on the Board of Directors of six InnoCal portfolio companies and is currently a Director of LifeMasters Supported Self Care, Maret Pharmaceuticals, Imagicast, and TriVida Corporation. Prior to joining InnoCal, Mr. Houlihan spent nine years with Boston Capital Ventures (BCV), an early stage venture capital partnership based in Boston. Mr. Houlihan received a BA in Political Science from Middlebury College and an MBA from the Boston University School of Management.

Gerry Messerschmidt, M.D. is a Board certified physician in Internal Medicine, Medical Oncology, and Hematology. His specialty training was at the National Institutes of Health (NIH), the National Cancer Institute and he headed the Experimental Hematology Section at the NIH contributing to the developing field of bone marrow stem cell biology and human transplantation. Dr. Messerschmidt has served as Executive Director of Medical Affairs at CIBA-Geigy, CEO of Kimeragen, and is currently the Executive Chairman of Wild-Type Enterprises.

Randolph (Randy) C. Steer, M.D., Ph.D. is an independent pharmaceutical and biotechnology consultant in clinical and regulatory affairs. He was formerly Chairman, President and CEO of Advanced Therapeutics Communications International and has served in senior medical capacities for major pharmaceutical companies such as Ciba Consumer Pharmaceuticals and Marion Laboratories. He serves on the Board of Directors of companies including Techne Corporation, BioCryst Pharmaceuticals, and Janus Pharmaceuticals. Dr. Steer received his M.D. degree from the Mayo Medical School and his Ph.D. from the University of Minnesota.

W. Leigh Thompson, PhD MD ScD FACP FCCM, was a Professor of Medicine and Director of Clinical Pharmacology and Critical Care at Case Western Reserve University after leaving Johns Hopkins University and NIH where he was on the faculty and developed and directed critical care units. From 1982 to 1994 at Eli Lilly and Company, he was responsible for worldwide research of human drugs, devices, diagnostics, and animal health products rising to Chief Scientific Officer. Since 1995 he has served on the Board of Directors of BAS, DepoMed, Inspire, LaJolla, Medarex, Ontogeny, Ophidian, Orphan Medical, and Tanabe Research Laboratories.